Abivax announces trading resumption of its ordinary shares on Euronext Paris

Rhea-AI Summary

Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.

The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.

Positive

• None.

Negative

• Potential dilution for existing shareholders through ADS offering

Abivax announces trading resumption of its ordinary shares on Euronext Paris

PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST.

Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share, €0.01 nominal value per share, of the Company, in the United States (the “Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.

***

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contacts:

Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878

***

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FAQ

When will Abivax (ABVX) resume trading on Euronext Paris?

Abivax will resume trading on Euronext Paris on July 24, 2025, at 3:30 p.m. CEST.

Why was Abivax (ABVX) stock trading halted?

Trading was halted to allow for investor allocation confirmations and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States.

What is the conversion ratio for Abivax's American Depositary Shares?

Each American Depositary Share (ADS) represents one ordinary share of Abivax, with a nominal value of €0.01 per share.

What is Abivax's main business focus?

Abivax is a clinical-stage biotechnology company developing therapeutics that harness natural regulatory mechanisms to modulate immune response in chronic inflammatory diseases.